Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg; cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg - capsule - 250 mg - active: cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide active: cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefaclor monohydrate 524.7mg equivalent to cefaclor 500 mg - capsule - 500 mg - active: cefaclor monohydrate 524.7mg equivalent to cefaclor 500 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - zoledronic acid monohydrate 0.0533 mg/ml equivalent to zoledronic acid 0.05 mg/ml - solution for infusion - 5 mg/100ml - active: zoledronic acid monohydrate 0.0533 mg/ml equivalent to zoledronic acid 0.05 mg/ml excipient: mannitol sodium citrate dihydrate water for injection - · treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures and to increase bone mineral density. · prevention of postmenopausal osteoporosis.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefotaxime sodium 1048.2mg equivalent to 1000 mg cefotaxime;   - powder for injection - 1000 mg - active: cefotaxime sodium 1048.2mg equivalent to 1000 mg cefotaxime  

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefotaxime sodium 2096.4mg equivalent to 2000 mg cefotaxime;   - powder for injection - 2000 mg - active: cefotaxime sodium 2096.4mg equivalent to 2000 mg cefotaxime  

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefotaxime sodium 524.1mg equivalent to 500 mg cefotaxime;   - powder for injection - 500 mg - active: cefotaxime sodium 524.1mg equivalent to 500 mg cefotaxime  

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 28.7 mg/ml equivalent to amoxycillin 25 mg/ml;  ; potassium clavulanate 8.6 mg/ml equivalent to clavulanic acid 6.25 mg/ml (plus 13% overage);  ;   - powder for oral suspension - 125mg,31.25mg/5ml - active: amoxicillin trihydrate 28.7 mg/ml equivalent to amoxycillin 25 mg/ml   potassium clavulanate 8.6 mg/ml equivalent to clavulanic acid 6.25 mg/ml (plus 13% overage)     excipient: aspartame citric acid guar gum hydrated silica lemon flavour 15020598 orange flavour 055301 ap0551 peach-apricot flavour 26f22 purified talc sodium citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 287mg equivalent to amoxycillin 250 mg;  ; potassium clavulanate 149mg equivalent to clavulanic acid 125 mg - film coated tablet - 250mg/125mg - active: amoxicillin trihydrate 287mg equivalent to amoxycillin 250 mg   potassium clavulanate 149mg equivalent to clavulanic acid 125 mg excipient: croscarmellose sodium ethylcellulose hypromellose magnesium stearate microcrystalline cellulose povidone purified talc   purified water titanium dioxide triethyl citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg;  ; potassium clavulanate 149mg equivalent to clavulanic acid 125 mg;   - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg   potassium clavulanate 149mg equivalent to clavulanic acid 125 mg   excipient: croscarmellose sodium ethylcellulose hypromellose magnesium stearate microcrystalline cellulose povidone purified talc   purified water titanium dioxide triethyl citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - rivaroxaban 10mg;   - film coated tablet - 10 mg - active: rivaroxaban 10mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 04f530012 sodium laurilsulfate - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.